UBS Group
TARS icon

UBS Group’s Tarsus Pharmaceuticals TARS Stock Holding History

UBS Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.63M Sell
73,528
-8,596
-10% -$549K ﹤0.01% 4241
2026
Q1 		$5.76M Buy
82,124
+15,225
+23% +$1.06M ﹤0.01% 3921
2025
Q4 		$5.48M Sell
66,899
-51,663
-44% -$3.86M ﹤0.01% 3940
2025
Q3 		$7.05M Buy
118,562
+90,056
+316% +$4.43M ﹤0.01% 3677
2025
Q2 		$1.15M Sell
28,506
-64,181
-69% -$2.89M ﹤0.01% 5322
2025
Q1 		$4.76M Buy
92,687
+31,380
+51% +$1.55M ﹤0.01% 3822
2024
Q4 		$3.39M Sell
61,307
-8,009
-12% -$364K ﹤0.01% 4210
2024
Q3 		$2.28M Buy
69,316
+41,343
+148% +$1.16M ﹤0.01% 3862
2024
Q2 		$760K Sell
27,973
-10,367
-27% -$349K ﹤0.01% 4664
2024
Q1 		$1.39M Buy
38,340
+7,847
+26% +$231K ﹤0.01% 4306
2023
Q4 		$617K Buy
30,493
+11,492
+60% +$192K ﹤0.01% 4923
2023
Q3 		$338K Buy
19,001
+1,539
+9% +$27.2K ﹤0.01% 4963
2023
Q2 		$316K Buy
17,462
+9,405
+117% +$150K ﹤0.01% 5178
2023
Q1 		$101K Buy
8,057
+1,199
+17% +$17.5K ﹤0.01% 5896
2022
Q4 		$101K Buy
6,858
+6,158
+880% +$102K ﹤0.01% 6096
2022
Q3 		$12K Hold
700
– – ﹤0.01% 8183
2022
Q2 		$10K Sell
700
-3,526
-83% -$52.9K ﹤0.01% 8003
2022
Q1 		$71K Buy
4,226
+1,142
+37% +$21.2K ﹤0.01% 6164
2021
Q4 		$70K Buy
3,084
+2,584
+517% +$67.2K ﹤0.01% 6627
2021
Q3 		$11K Buy
+500
New +$12.4K ﹤0.01% 7907
2021
Q2 		– Sell
-2,496
Closed -$80K – 9816
2021
Q1 		$80K Buy
2,496
+1,171
+88% +$43.3K ﹤0.01% 6135
2020
Q4 		$55K Buy
+1,325
New +$37.7K ﹤0.01% 6104

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group's TARS Position: Q2 2026 in Review

UBS Group reduced its Tarsus Pharmaceuticals (TARS) stake by 10% in Q2 2026, selling an estimated $549K and leaving 73,528 shares worth $4.63M. The position accounts for ﹤0.01% of the portfolio, ranked #4241.

UBS Group first reported a position in TARS in Q4 2020 and has held it in 22 quarters since. The position peaked at $7.05M in Q3 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • UBS Group held 73,528 shares of Tarsus Pharmaceuticals worth $4.63M as of Q2 2026.
  • UBS Group sold 8,596 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $549K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4241 holding.
  • UBS Group first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • UBS Group's Tarsus Pharmaceuticals position peaked at $7.05M in Q3 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.